基线慢性肾脏病分期与开窗腔内动脉瘤修复术后短期和长期结局的关联
单中心回顾性分析2012至2022年184例采用Cook ZFEN装置行标准开窗腔内动脉瘤修复术(FEVAR)的患者,按术前CKD 1-2期与CKD 3-5期分组比较。CKD 3-5期患者1年和5年总生存率及免于透析率更低,而术后急性肾损伤、肾动脉通畅、内漏、再干预及瘤囊回缩等方面无显著差异。
要点
- CKD 3-5期患者1年生存率82.3% vs CKD 1-2期95.1%,5年生存率55.4% vs 70.8%。
- CKD 3-5期患者1年免于慢性透析率94.4% vs CKD 1-2期100%,5年84.7% vs 100%。
- 多因素模型中CKD 4-5期与全因死亡独立相关(HR 6.39,95%CI 2.26-18.05,P<0.01)。
核心结论
- 术前CKD状态未对FEVAR术后动脉瘤相关结局的耐久性或技术成功产生负面影响。
- CKD分期加重与FEVAR术后1年和5年总生存率及免于透析率降低相关,而30天或长期技术性动脉瘤结局无统计学显著差异。
研究设计与样本
- 单中心回顾性连续病例分析,纳入2012年至2022年接受Cook装置标准FEVAR的患者184例,其中男性82%,平均随访34.3个月。
- 按术前CKD分期分为CKD 1-2期组与CKD 3-5期组,CKD 3-5期组77例(42%)。
- 主要结局为术后急性肾损伤(AKI),次要结局包括30天围手术期并发症及1年和5年总生存、透析、肾靶动脉通畅、内漏和再干预(Kaplan-Meier法)。
- 采用多因素Cox比例风险模型评估CKD 3期和CKD 4-5期与全因死亡的关联,并控制基线特征差异。
主要发现
- CKD 3-5期组较CKD 1-2期组年龄更大(75.2岁 vs 73.0岁,P=0.04)、术前肌酐更高(1.6 mg/dL vs 0.9 mg/dL,P<0.01)、肾动脉开口钙化更多(37.7% vs 21.5%,P=0.02)。
- 围手术期CKD 3-5期组估计失血量更多(342 mL vs 228 mL,P=0.01)、手术时间更长(186 min vs 162 min,P=0.04)、住院时间更长(3天 vs 2天,P<0.01)。
- Kaplan-Meier估计1年生存率CKD 3-5期组82.3% vs CKD 1-2期组95.1%(P<0.01),5年生存率55.4% vs 70.8%(P=0.02)。
- 1年免于慢性透析率CKD 3-5期组94.4% vs CKD 1-2期组100%(P=0.015),5年84.7% vs 100%(P<0.01)。
- 术后AKI率CKD 1-2期组6.5% vs CKD 3-5期组14.3%(P=0.13),长期肾动脉通畅、再干预、I型或III型内漏、平均瘤囊回缩及随访CT总次数两组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated endovascular aneurysm repair (FEVAR) is a well-established treatment approach for juxtarenal and short-neck infrarenal aortic aneurysms. Recommendations and clinical outcomes are lacking for offering FEVAR in patients with chronic kidney disease (CKD). We aimed to compare short- and long-term outcomes for patients with none-to-mild versus moderate-to-severe CKD undergoing FEVAR. METHODS: We retrospectively reviewed consecutive patients undergoing standard FEVAR with Cook devices at a single institution. The cohort was stratified by preoperative CKD stage none-to-mild or moderate-to-severe (CKD 1-2 and CKD 3-5, respectively). The primary outcome was postoperative acute kidney injury (AKI). Secondary outcomes included 30-day perioperative complications, 1- and 5-year rates of overall survival, dialysis, renal target artery patency, endoleak, and reintervention assessed by the Kaplan-Meier method. Aneurysm sac regression, number of surveillance computed tomography (CT) scans, and CKD stage progression were assessed at latest follow-up. Multivariate Cox proportional hazards modeling was used to evaluate the association of CKD stage 3 and stage 4-5 with all-cause mortality, controlling for differences in baseline characteristics. RESULTS: From 2012- to 2022, 184 patients (of which 82% were male) underwent FEVAR with the Cook ZFEN device (mean follow-up 34.3 months). Group CKD 3-5 comprised 77 patients (42%), was older (75.2 vs. 73.0 years, P = 0.04), had increased preoperative creatinine (1.6 vs. 0.9 mg/dL, P < 0.01), and demonstrated increased renal artery ostial calcification (37.7% vs. 21.5%, P = 0.02) compared with Group CKD 1-2. Perioperatively, CKD 3-5 sustained higher estimated blood loss (342 vs. 228 ml, P = 0.01), longer operative times (186 vs. 162 min, P = 0.04), and longer length of stay (3 vs. 2 days, P < 0.01). Kaplan-Meier 1- and 5-year survival estimates were lower for CKD 3-5 (82.3% vs. 95.1%, P < 0.01 and 55.4% vs. 70.8%, P = 0.02). Fewer CKD 3-5 patients remained free from chronic dialysis at 1 year (94.4% vs. 100%, P = 0.015) and 5 years (84.7% vs. 100%, P < 0.01). There were no significant differences in postoperative AKI rate (CKD 1-2 6.5% vs. CKD 3-5 14.3%, P = 0.13), long-term renal artery patency, reinterventions, type I or III endoleak, mean sac regression, or total follow-up CT scans between groups. CKD stage progression occurred in 47 patients (31%) at latest follow-up but did not differ between stratified groups (P = 0.17). On multivariable modeling, age (hazard ratio 1.05, 95% confidence interval 1.01-1.09, P = 0.02) and CKD stage 4-5 (hazard ratio 6.39, 95% confidence interval 2.26-18.05, P < 0.01) were independently associated with mortality. CONCLUSIONS: Preoperative CKD status did not negatively impact the durability or technical success related to aneurysm outcomes after FEVAR. Worsening CKD stage was associated with lower 1- and 5-year overall survival and freedom from dialysis after FEVAR with no statistically significant differences in 30-day or long-term technical aneurysm outcomes.
引用
- Dossabhoy SS, Sorondo SM, Fisher AT, et al. Association of Baseline Chronic Kidney Disease Stage With Short- and Long-Term Outcomes After Fenestrated Endovascular Aneurysm Repair. Ann Vasc Surg. 2023. PMID: 37586562. doi:10.1016/j.avsg.2023.07.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。